Periprocedural cardiopulmonary bypass or venoarterial extracorporeal membrane oxygenation during transcatheter aortic valve replacement: A systematic review

Saraschandra Vallabhajosyula, Sri Harsha Patlolla, Harigopal Sandhyavenu, Saarwaani Vallabhajosyula, Gregory W. Barsness, Shannon M Dunlay, Kevin L. Greason, David Holmes, Mackram Eleid

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background—There are limited data on the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) or cardiopulmonary bypass (CPB) to provide hemodynamic support periprocedurally during transcatheter aortic valve replacement. This study sought to evaluate patients receiving transcatheter aortic valve replacement with concomitant use of CPB/VA-ECMO. Methods and Results—We systematically reviewed the published literature from 2000 to 2018 for studies evaluating adult patients requiring CPB/VA-ECMO periprocedurally during transcatheter aortic valve replacement. Studies reporting short-term and long-term mortality were included. Given the significant methodological and statistical differences between published studies, meta-analysis of the association of CPB/VA-ECMO with mortality was not performed. Of the 537 studies identified, 9 studies representing 5191 patients met our inclusion criteria. Median ages were between 75 and 87 years with 33% to 75% male patients. Where reported, the Edwards SAPIEN™ transcatheter heart valve was the most frequently used. A total of 203 (3.9%) patients received periprocedural hemodynamic support with CPB/VA-ECMO. Common indications for CPB/VA-ECMO included left ventricular or aortic annular rupture, rapid hemodynamic deterioration, aortic regurgitation, cardiac arrest, and left main coronary artery obstruction. The use of CPB/VA-ECMO was predominantly an emergent strategy and was used for durations of 1 to 2 hours. Short-term mortality (in-hospital and 30-day) was 29.8%, and 1-year mortality was 52.4%. Major complications such as bleeding, vascular injury, tamponade, stroke, and renal failure were noted in 10% to 50% of patients. Conclusions—CPB/VA-ECMO was used in 4% in the early experience of patients undergoing transcatheter aortic valve replacement, most commonly for periprocedural complications. There are limited data on preprocedural planned use of VA-ECMO, and the characteristics of this population remain poorly defined.

Original languageEnglish (US)
Article numbere009608
JournalJournal of the American Heart Association
Volume7
Issue number14
DOIs
StatePublished - Jul 1 2018

    Fingerprint

Keywords

  • Cardiogenic shock
  • Cardiopulmonary bypass
  • Critical care
  • Mechanical circulatory support
  • Transcatheter valve implantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this